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As part of its mission to promote the best surgical care for cancer patients, the European Society of
Surgical Oncology (ESSO) has been developing multiple programmes for clinical research along with its
educational portfolio. This position paper describes the different research activities of the Society over
the past decade and an action plan for the upcoming five years to lead innovative and high quality
surgical oncology research. ESSO proposes to consider pragmatic research methodologies as a comple-
ment to randomised clinical trials (RCT), advocates for increased funding and operational support in
conducting research and aims to enable young surgeons to be active in research and establish part-
nerships for translational research activities.
© 2019 Published by Elsevier Ltd.Background and rationale of ESSO
In 1981, the European Society of Surgical Oncology (ESSO) was
founded to benefit cancer patients through the science and practice. Evrard).of surgical oncology, promoting education, research and leadership
in multidisciplinary care. Since then, ESSO has steadily increased its
membership and educational portfolio, reaching out to the global
surgical community. It has successfully positioned itself as the
leading society for surgical oncologists in Europe and as a key
player in the oncological arena through its research activities,
which increased progressively during the last decade. The
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icant correlation between the number of scientific publications and
the proportion of cancer specific mortality per country [1]. In a
subset analysis of countries that have less than 1000 publications
per year, even a modest increase of a few hundred publications is
correlated with a decrease of cancer specific mortality [2].
However, the field of cancer research has becomemore complex
due to advances in technology, (molecular) biology and immune-
oncology, making the role of high quality surgical research even
more relevant as theworld struggles to balance the cost and benefit
of treatments.
The key research strategies of ESSO include optimal utilisation of
national registries to benchmark surgical practices across Europe,
prospective clinical and translational research and partnership
with international surgical societies to integrate research in surgi-
cal education and training. This ESSO position paper discusses
challenges in surgical oncology research and presents a plan of
action for the coming five years on how to overcome these hurdles.
Challenges in clinical research in surgical oncology
There is great need for research to demonstrate and establish
the impact of surgery in an oncological field that is mainly driven by
advances in cancer biology and immune-oncology, yet, only 1% of
cancer patients is recruited into surgical oncology trials in Europe.
Conducting research in surgical oncology has always been chal-
lenging due to a number of surgery-related reasons further detailed
below [3].
Variability of complex surgical procedures
The complexity of and variation in disease and accompanying
inter-surgeon variability makes it more difficult to produce uniform
and standardised outcome measures compared to research
focussed on non-surgical treatment. Surgical expertise, learning
curve effects, lack of systematic, consistent reports of operative
findings and pathological outcomes all contribute to heterogeneous
data. This amounts to (statistical) challenges when comparing
different surgical treatment strategies.
Trial design for surgical research questions
Defining the research question, endpoint and appropriate trial
design are the first steps for developing newclinical trials. Although
the gold standard for researching a new treatment is the rando-
mised clinical trial (RCT), this is not always a possibility when
investigating surgical treatment options. The randomisation pro-
cess often lacks equipoise for both surgeons and patients, and pa-
tients are generally not willing to accept randomisation to the
control arm when a new treatment is available. In 2006, surgical
phase III trials represented only 8% of all publications,1 in 5 surgical
studies was prematurely closed and 44% were never published [4].
Less than 50% of surgical trials meet the CONSORT criteria for non-
pharmacological trials. Recently, the CONSORT checklist was
reduced from 25 items to 10, hoping to improve compliance [5].
Still, the quality of reporting in the surgical literature is poor, and
feasible alternative methodologies somewhere on the spectrum
between retrospective reports and RCTs are underused, especially
in phases II and IV [3]. The role of surgical journals here is crucial.
Some of the most highly rated journals are still reluctant to publish
well designed prospective phase II studies, even though they are
superior to larger retrospective series. This is one of the major
reasons why education of surgeons and editors/reviewers of jour-
nals is needed to reach high quality research.Funding
There is a lack of financial and political priority for surgical trials,
even though surgery has an enormous impact on cancer patients.
Of all public funding towards clinical research in oncology, less than
5% is devoted to surgical research [4]. There is little commercial
incentive for companies to fund surgical trials, thus, support is
needed from non-profit organisations, corporate social re-
sponsibility activities and governments. Alternatively, a stronger
collaborationwith the medical oncology community could result in
more funds, since they do receive substantial support from the
pharma industry. This seems a reasonable solution, as the multi-
disciplinary approach is already the standard in the treatment of
patients. For example, a patient suffering from metastasised colo-
rectal cancer can expect improvement not only from new drugs but
also from a more advanced surgical strategy, such as the new
parenchyma-sparing liver surgery [6]. Both types of treatment need
trials to confirm their efficacy.
Furthermore, any research into (neo-)adjuvant systemic therapy
cannot be expected to yield scientifically sound results, if equal
quality of surgery in both arms cannot be confirmed. There is an
urgent need for multidisciplinary leaders of cancer research in
Europe to construct a shared vision and a shared commitment to an
integrated approach in cancer care. For this, a joint effort in
securing funds and support for clinical research is essential.
Impact of advances in (molecular) biology and technology
There has been a seismic shift in the understanding and treat-
ment of cancer, brought on by advances in molecular biology and
immune-oncology [7]. Much of the global funding and research
efforts have been focused on personalised medicine and new
combinations of chemo-, radio- and immunotherapy. Though the
role of high quality surgery at all stages of cancer has not dimin-
ished, conducting purely surgical trials has become even more
difficult. The role of surgeons within research has shifted towards
becoming “technicians”, delivering samples for biobanks and
translational research. This should be embraced by surgeons and
seen as a chance to develop new partnerships with biologists and
imaging and technology experts. Young investigators interested in
academic careers can become part of innovative research from such
fruitful collaborations. An example of this is new research into the
impact of local treatments on activating the immune system, which
is a real chance for surgeons to become leaders in the current
molecular revolution.
ESSO's response to challenges in surgical research
A pan-European infrastructure focussing on the issues described
previously is needed to define an agenda for surgical oncology
research and to introduce a culture of research among future sur-
geons. Research methodology has to be adapted in order to achieve
this; RCTs should remain the gold standard, but at the same time, a
more pragmatic approach should be explored to increase the
chances of successfully producing high level evidence for innova-
tive cancer surgery (Fig. 1) [8].
Utilising national cancer registries
The EURECCA project (acronym for European Registration of
Cancer Care) was ESSO's first research initiative. This project is a
framework to develop a prospective European audit structure, with
the goal of improving treatment strategies and making them more
accessible to European cancer patients. Through an international
network, EURECCA builds a comprehensive approach to capture
Fig. 1. Committees of ESSO involved in research; ESSO e European Society of Surgical
Oncology; EURECCA e European Registry for Cancer Care; ESSO CRC e ESSO Clinical
Research Committee; EORTC e European Organization for Research and Treatment of
Cancer; SURCARE e High Quality Standards for Prospective Surgical Clinical Research;
EYSAC e ESSO Young Surgeons Alumni Club; SIOG e International Society of Geriatric
Oncology.
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benchmark surgical quality and clinical practices. Some EURECCA
projects are described below to provide an insight in its procedures.Colorectal cancer
Two international studies using population-based data were
conducted to investigate adjuvant treatment variation between
European countries. For the first, data was collected from all pa-
tients diagnosed with stage II colon cancer between 2004 and 2009
in the Netherlands, Denmark, Sweden, England, Ireland and
Belgium (n¼ 59,154) [9]. The proportion of patients receiving
adjuvant chemotherapy ranged from 7% to 29%. No clear pattern
was found between the proportion of patients receiving adjuvant
chemotherapy and survival. For the second study, data was
collected from all patients diagnosed with stage I-III rectal cancer
(n¼ 57,120). The proportion of patients receiving preoperative
radiotherapy ranged from 8% to 60% and postoperative chemo-
therapy ranged from 8% to 39%. These two studies demonstrate that
the large differences in treatment strategies did not lead to differ-
ences in survival.
Colon cancer in older patients represents a major public health
issue. As older patients are seldom included in clinical trials, the
optimal treatment for these patients remains unclear. In order to
describe treatment variation of patients with colon cancer aged 80
years and older, data from five European cancer registries were
obtained (n¼ 50,761) [10]. Almost all patients underwent surgery
but the proportion of adjuvant chemotherapy varied considerably.
Despite a higher proportion of patients receiving adjuvant
chemotherapy, poorer survival outcomes were observed in
Belgium.Breast cancer
Older patients are also poorly represented in breast cancer
research. This EURECCA comparison assessed whether variation in
treatment patterns may be associated with variation in survival.
The population-based study included patients aged 70 years or
older with non-metastatic breast cancer from cancer registries in
the Netherlands, Belgium, Ireland, England and Poland
(n¼ 236,015). The proportion of patients with stage I breast cancer
receiving endocrine therapy ranged from 20% to 85%, though no
differences in survival were observed, suggesting gross over-
treatment. On the other hand, the proportion of patients with stage
III breast cancer receiving surgery ranged from 50% to 78%, which
was accompanied by differences in survival, suggesting potential
undertreatment [11].Pancreatic cancer
Pancreatic cancer is one of the fewmalignancies with increasing
incidence and mortality rates. The aim of this study was to describe
variation in adjuvant chemotherapy and survival after primary
tumour resection for stage I and II pancreatic cancer (n¼ 3901). The
proportion of patients receiving adjuvant chemotherapy ranged
from 41% to 70%. Ninety-day mortality ranged from 1% to 14%, but
overall survival (OS) did not differ. This study provides a clear
insight into clinical practice in the EURECCA Pancreas consortium,
and differences in adjuvant chemotherapy and outcomes provide a
basis for further investigation.
Oesophageal and gastric cancer
Two recent comparisons of treatment and outcomes in patients
with metastatic gastric cancer and in patients aged 70 years or
older were conducted. In the study regarding metastatic gastric
cancer (n¼ 17,493), the proportion of gastric resections varied from
8% to 20%. Administration of chemotherapy ranged from 37% to
62%. Higher proportions of surgery and chemotherapy seem to be
associated with better survival.
Prospective international registries and vision for the future
Currently, there are two prospective data collection projects
within EURECCA. The International Watch and Wait Database
(IWWD) is currently open for inclusion and data are collected
regarding rectal cancer patients in whom total mesorectal excision
(TME) surgery was delayed or omitted after neoadjuvant therapy
[12]. In the International Nipple Sparing Mastectomy Registry
(INSPIRE) dataset, recently closed for inclusion, patients with breast
cancer who undergo a nipple sparing mastectomy with immediate
reconstruction are entered to assess the oncological outcome,
complication rate and aesthetic outcomes. Both registries are ex-
amples of alternative strategies to RCTs that still provide valid and
unbiased scientific insights. Since RCTs are usually not a viable
option for researching new surgical treatments, due to lack of
funding and unwillingness to randomise, prospective databases
provide the solution for developing evidence based treatments.
Part of EURECCA's strategy for the future is setting up more pro-
spective registries to gather systematic and valid evidence for new
surgical treatments.
Another important aspect of EURECCA's goals are continuing to
provide comparisons of treatment strategies between different
European countries. By doing so, awareness is created and the large
variation is thought-provoking and used to generate new hypoth-
eses for future studies.
Collaboration with EORTC: the SURCARE initiative
In 2015, a Clinical Research Committee (CRC) was set up to
partner with the European Organization for Research and Treat-
ment of Cancer (EORTC) in order to systematically develop high
quality prospective surgical research. The ESSO CRC is composed of
ESSOmembers that are actively engaged in clinical research, among
them several members of the European Young Surgeons Alumni
Club (EYSAC).
EORTC and ESSO share a common vision to improve the quality
of surgical research in Europe. They also have complementary
expertise; ESSO has a huge network of surgeons, scientific guide-
lines for high quality surgical care and an extensive educational
portfolio, while EORTC has expertise in the scientific and opera-
tional aspects of international multidisciplinary clinical research. A
partnership was established between the two to build SURCARE
[13], an infrastructure for quality assurance in prospective clinical
research. Through SURCARE, ESSO and EORTC articulate the need
for more precision in cancer surgery through prospective, high
Fig. 2. ESSO's for pillars of action for improving clinical research in surgery.
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are most relevant for individual patients. Two projects stemmed
from this partnership.
CLIMB EORTC 1409/ESSO 01
CLIMB is a prospective colorectal liver metastasis database with
an integrated quality assurance programme. Patients are included if
they have unresectable, borderline resectable or initially unre-
sectable colorectal liver metastasis, as determined by a multidis-
ciplinary team (MDT) meeting. The primary endpoint is the 30- and
90-day surgical complications, the secondary endpoints are long-
term outcomes. Currently, 210 patients are registered, and 126
patients (60%) underwent at least one liver surgery. Most
commonly reported complications include wound, urinary tract
and intra-abdominal infections, bile leak, post hepatectomy liver
failure, anaemia and fluid retention (NCT02218801).
DREAM EORTC 1527/JCOG 1609 INT/ESSO 02
DREAM, diffusion weighted MRI assessment of liver metastasis
to improve surgical planning is the first collaborative study be-
tween ESSO, EORTC and JCOG, the largest and most influential
clinical research group in Japan. Using standard liver imaging and
surgery, patients with borderline resectable or unresectable colo-
rectal liver metastases with available CT scan, T1/T2 weighted,
Diffusion Weighted (DW) and contrast enhanced (CE) MRI (multi-
parametric MRIs) will be assessed by an MDT for the appropriate
treatment strategy. Treatment naïve patients and those who have
started their chemotherapy are both eligible. Both the CT scan and
multiparametric MRI at two time points (one before the start of
chemotherapy and one before surgery) must be available. All pa-
tients who then undergo liver surgery will be followed within
DREAM for 2 years. The primary focus of the study will be the
analysis of confirmed disappearing liver metastases (cDLM),
defined as lesions that disappeared after chemotherapy on both CT
scan and multiparametric MRIs. The primary objective is to assess
the negative predictive value of preoperative DW-MRI, T1/T2, CE-
MRI and standard CT scan combined for identifying non-viable le-
sions among cDLMs. The true status of the lesions will be assessed
by histopathology among those resected and by follow-up imaging
among those left in situ. Accrual is on-going (NCT02781935).
Focus on geriatric patients
ESSO has also collaborated with the International Society of
Geriatric Oncology (SIOG) surgical task force to create “Go Safe:
Geriatric Oncology Surgical Assessment and Functional Recovery
after Surgery”. This is an international prospective registry on how
frailty, comorbidities, and malnourishment are associated with
clinical outcome after surgery in older patients. This registry fo-
cuses on patients’ quality of life, as well as functional recovery. This
is an important initiative to clarify surgical issues among elderly
cancer patients.
Empowering young surgeons
One of the core missions of ESSO is to pave the way for a new
generation of surgeons who will not only learn to operate skilfully
but also become future key opinion leaders with a deep under-
standing of cancer biology and clinical research methodology. For
this, the European Young Surgeons Alumni Club (EYSAC) has the
following research activities.
CORSiCA: complete pathologic response rectal cancers
This is the first EYSAC International, multicentre, retrospective
cohort study including rectal cancer patients treated from 2012 to2017 who underwent TME or local excision with a pathological
diagnosis consistent with ypT0, independently fromN status. So far,
729 rectal cancer patients have been included in the database from
45 European, Australian, and South American centres. More precise
results will be presented after full collection of the data. Pre-
liminary results were presented during the best abstracts session of
the 38th ESSO congress in Budapest, Hungary (NCT03351959).
Young for young (Y4Y)
Y4Y is a project of young surgeons for young patients. In the
majority of malignancies, the incidence of cancer is strongly linked
to age. However, cancer incidence among patients younger than 40
years is also increasing. Very little is known for the majority of
these patients, regarding prognosis and over- and undertreatment.
These factors, together with quality of life analysis focussed on
specific needs of these patients in the 21st century, will be inves-
tigated by an international group of young surgeons under the ESSO
and EYSAC umbrella.
Vision for the future (5-year plan)
Being involved in clinical research is a major commitment of
ESSO and producing high quality and robust evidence is our re-
sponsibility. However, challenges remain, and a clear strategy is
needed if we are to be successful in our mission. The plan of action
for the coming five years consists of 4 pillars (Fig. 2).
1. Money is scarcely available in surgical research. Therefore, sur-
geons need pragmatic models without compromising quality
and science. ESSO aims to collaboratemorewith oncologists and
methodologists and lobby for alternative funding sources, using
the impact of cancer surgery on medical oncology and surgical
quality in patient outcomes as leverage.
2. As resources are limited, surgeonsmust carefully select the topic
and endpoints of their research, focussing on unmet needs and
practice changing questions. Involving young surgeons and
multidisciplinary teams to target the right question is key for the
future of our research activities. ESSO's CRC and EYSAC provide
an environment for young investigators to develop new ideas
and optimise design of their studies.
3. In order to develop well-designed and efficient studies, wemust
enhance our networking. This means sharing our vision and
strategy for oncology research and surgical leadership.
Strengthening partnerships will be needed with surgical soci-
eties like the SSO to harmonize standards of quality and
implement a culture of research among surgeons.
4. Surgeons underestimate their role in biological research. Sur-
gery presents a unique opportunity to collect samples from
S. Evrard et al. / European Journal of Surgical Oncology 45 (2019) 1515e1519 1519primary tumours, peripheral normal tissue and metastases as
well as liquid biopsies. We must increase our involvement in
defining scientific questions and establishing standards of
quality in prospective biobanking processes. Collaborating with
biological research teams is an opportunity for excellent trans-
lational research linked high quality surgery, molecular biology
and the use of technology. Surgeons can be the drivers of such
research, like in the translational project of the DREAM study.
Fundamental research seems to indicate that local treatments
like surgery affect the immune response and could interfere
with the progression of cancer [14]. Surgeons have a fantastic
opportunity to innovate and lead ground-breaking progress by
utilising the techniques they are already familiar with to gain a
deeper level of understanding of the biological mechanisms of
cancer.Conclusion
A pan-European infrastructure focussing on the issues described
previously is needed to define an agenda for surgical oncology
research and to introduce a culture of research among future sur-
geons. Protocol-driven studies that are well designed with accurate
and informative clinical data must be the rule rather than the
exception. To achieve this, research methodology has to be adapt-
ed; RCTs should remain the gold standard, but at the same time, a
more pragmatic approach should be explored to increase the
chances of successfully producing high level evidence for innova-
tive cancer surgery. ESSO aims to address these challenges together
with its partners, by advocating for surgical research funding,
quality assurance, education, global and multidisciplinary collabo-
rations, especially for translational research. ESSO's commitment to
high quality surgical research must live up to the complexity of a
disease it is willing to fight.
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